ZB716(Fulvestrant-3 Boronic Acid)
98%
- Product Code: 109989
CAS:
1853279-29-4
| Molecular Weight: | 634.59 g./mol | Molecular Formula: | C₃₂H₄₈BF₅O₄S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
ZB716, a fulvestrant-3 boronic acid derivative, is primarily explored in the field of cancer research, particularly for targeting estrogen receptor-positive (ER+) breast cancer. It functions as a selective estrogen receptor degrader (SERD), effectively binding to estrogen receptors and promoting their degradation, thereby inhibiting estrogen-dependent cancer cell growth. This compound is being investigated for its potential to overcome resistance to traditional endocrine therapies, offering a promising approach for patients with advanced or metastatic breast cancer. Additionally, its boronic acid moiety may enhance binding affinity and pharmacokinetic properties, making it a candidate for further development in targeted cancer therapies. Research is ongoing to evaluate its efficacy, safety, and potential clinical applications.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | ฿56,862.00 |
+
-
|
ZB716(Fulvestrant-3 Boronic Acid)
ZB716, a fulvestrant-3 boronic acid derivative, is primarily explored in the field of cancer research, particularly for targeting estrogen receptor-positive (ER+) breast cancer. It functions as a selective estrogen receptor degrader (SERD), effectively binding to estrogen receptors and promoting their degradation, thereby inhibiting estrogen-dependent cancer cell growth. This compound is being investigated for its potential to overcome resistance to traditional endocrine therapies, offering a promising approach for patients with advanced or metastatic breast cancer. Additionally, its boronic acid moiety may enhance binding affinity and pharmacokinetic properties, making it a candidate for further development in targeted cancer therapies. Research is ongoing to evaluate its efficacy, safety, and potential clinical applications.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :